CN Group

Sinopharm, officially known as the China National Pharmaceutical Group Co., Ltd. (CNPGC), is a massive state-owned enterprise and the largest healthcare group in China. The company operates across the entire pharmaceutical value chain, including research and development, manufacturing, logistics, and retail distribution. Sinopharm gained significant global prominence for its development of inactivated COVID-19 vaccines, which were among the first to receive WHO emergency use listing. Beyond vaccines, the group is a major producer of essential medicines, blood products, and medical devices, serving both domestic and international markets. With a vast network of subsidiaries and research institutes, Sinopharm remains a central pillar of China's public health infrastructure and a key player in the global life sciences industry.